Hadassah

Hadassah Hosts First Human Trial with Drug to Fight Nasty Bacterial Infection

Monday, Aug 14 2017

Immuron, an Australian biopharmaceutical company, has received approval from the Hadassah Medical Organization’s ethics committee and Israel’s Ministry of Health to begin its first clinical trial with a new drug to fight a bacterial infection called Clostridium Difficile (CDI).

CDI, often also called C. difficile, is caused by a bacterial toxin that inflames the colon. It is especially found in hospitals and long-term, in-patient care facilities. Approximately 500,000 people annually contract CDI in the U.S. alone and about 20 percent experience a recurrence.

The new product, called IMM-529, is a naturally produced biological antibody, intended to prevent and treat CDI, as well as stop recurrence. As a polyclonal antibody, it generates highly specific antibodies to fight the three main sources of CDI: Toxin B, the highly infectious spores, and the vegetative cells in the gut. In addition, IMM-529 has been shown to rebalance the diversity of bacteria in the gut, which is often disrupted by antibiotics.

This first-ever human study will assess whether IMM-529 is safe and well tolerated by the participants and will also evaluate the preliminary efficacy of IMM-529. Pre-clinical studies with mice at Monash University in Melbourne, Australia, revealed 80 percent efficacy in preventing and treating CDI and 77.8 percent success in preventing recurrence. The control group of mice, in contrast, which only received the standard-of-care antibiotic, vancomycin, experienced a mortality rate of 88.9 percent.

In this human trial, 60 patients who have been diagnosed with CDI and treated with standard-of-care antibiotics, will be enrolled within three weeks of their diagnosis. Some will be randomly selected to receive IMM-529 three times daily and the others will receive a placebo for 28 days.

Read more at: http://www.immuron.com/assets/Uploads/Red-Chip-C-Difficile-Analyst-Report-Jan-2016.pdf

Read about another IMMURON clinical trial at Hadassah http://www.hadassah.org/news-stories/fatty-liver-us-trials.html

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Thursday, Feb 21 2019

Hadassah Heart Specialist Performs Revolutionary Repair of Fatal Aortic Condition

Most people with aneurysms have to choose between very risky surgery or waiting for their aneurysm to rupture. Now there’s a new method to repair the deadly medical condition.

READ MORE ›
alt_text

Wednesday, Feb 20 2019

Jerusalem Basketball Star Undergoes Knee Surgery at Hadassah

Chris Johnson, a star basketball player with Hapoel Bank Yahav Jerusalem, underwent successful knee surgery at Hadassah Hospital Mount Scopus.

READ MORE ›
alt_text

Tuesday, Feb 19 2019

Marathoner Is Helicoptered to Hadassah After Collapsing During Race

Shahar David, age 46, had planned to run 10 kilometers in the Dead Sea Marathon, but he collapsed after kilometer 6. A helicopter transported him to Hadassah Hospital Ein Kerem, where he underwent an emergency cardiac catheterization that saved his life.

READ MORE ›
alt_text

Thursday, Feb 7 2019

Six Miscarriages, a Severe Liver Disease, and a Dream

Oshrat Ohana Nagar was a busy newspaper journalist, a self-proclaimed workaholic, and a mother of two children. Shortly after the birth of her second child, however, she began to experience pain throughout her body.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More